UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

The New England journal of medicine, 2018-09, Vol.379 (11), p.1007-1016

2018

Volltextzugriff (PDF)

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy

Orphanet journal of rare diseases, 2018-12, Vol.13 (1), p.225-225, Article 225

2018

Volltextzugriff (PDF)

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy

Clinical Medicine Insights. Cardiology, 2017, Vol.2017 (11), p.1179546817730322-1179546817730322

2017

Volltextzugriff (PDF)

Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)

Circulation. Heart failure, 2017-06, Vol.10 (6)

2017

Volltextzugriff (PDF)

Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder

Journal of child and adolescent psychopharmacology, 2013-10, Vol.23 (8), p.545

2013

Volltextzugriff (PDF)

Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study

Journal of child and adolescent psychopharmacology, 2013-10, Vol.23 (8), p.531

2013

Volltextzugriff (PDF)

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT

ESC Heart Failure, 2021-10, Vol.8 (5), p.3875-3884

2021

Volltextzugriff (PDF)

Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: Clinical and methodological implications

Journal of affective disorders, 2013-01, Vol.144 (1), p.171-175

2013

Volltextzugriff (PDF)

Reply to ‘Effects of tafamidis on heart failure hospitalization: The tale of the dog that did not bark’

European journal of heart failure, 2024-02, Vol.26 (2), p.526-527

2024

Volltextzugriff (PDF)

Free Light-Chain Levels in Patients with Transthyretin Amyloid Cardiomyopathy in Attr-ACT

Blood, 2021-11, Vol.138 (Supplement 1), p.3787-3787

2021

Volltextzugriff (PDF)

Abstract 13149: Survival Benefit With Higher Dose Tafamidis in Patients With Hereditary and Wild-type Transthyretin Amyloid Cardiomyopathy

Circulation (New York, N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A13149-A13149

2020

Volltextzugriff (PDF)

Five-year Survival With Tafamidis In Patients With Transthyretin Amyloid Cardiomyopathy

Journal of cardiac failure, 2022-04, Vol.28 (5), p.S102-S102

2022

Volltextzugriff (PDF)

Response by Elliott et al to Letter Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”

Circulation. Heart failure, 2022-07, Vol.15 (7), p.e009637-e009637

2022

Volltextzugriff (PDF)

TAFAMIDIS DELAYS PROGRESSION OF CARDIAC DYSFUNCTION IN PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS: NON-INVASIVE PRESSURE VOLUME ANALYSIS OF THE ATTR-ACT TRIAL

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.341-341

2023

Volltextzugriff (PDF)

EFFECT OF TAFAMIDIS ON RENAL FUNCTION IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN ATTR-ACT

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.336-336

2023

Volltextzugriff (PDF)

EFFICACY OF TAFAMIDIS IN PATIENTS 80 YEARS AND OLDER WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN ATTR-ACT

Journal of the American College of Cardiology, 2023-03, Vol.81 (8), p.337-337

2023

Volltextzugriff (PDF)

Improved long‐term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms

European journal of heart failure, 2023-11, Vol.25 (11), p.2060-2064

2023

Volltextzugriff (PDF)

Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial

Amyloid, 2017-01, Vol.24 (1), p.30-36

2017

Volltextzugriff (PDF)

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy

Amyloid, 2016-07, Vol.23 (3), p.178-183

2016

Volltextzugriff (PDF)

Abstract 12239: Improvement in Measures of Disease Progression With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)

Circulation (New York, N.Y.), 2021-11, Vol.144 (Suppl_1)

2021

Volltextzugriff (PDF)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

Circulation. Heart failure, 2022-01, Vol.15 (1), p.e008193-e008193

2022

Volltextzugriff (PDF)

EVALUATION OF TRANSTHYRETIN TETRAMER STABILIZATION AND TTR PLASMA CONCENTRATIONS IN THE TAFAMIDIS IN TRANSTHYRETIN CARDIOMYOPATHY CLINICAL TRIAL (ATTR-ACT)

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.525-525

2021

Volltextzugriff (PDF)

Abstract 15528: Tafamidis Free Acid 61 Mg in Patients With Transthyretin Amyloid Cardiomyopathy

Circulation (New York, N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A15528-A15528

2020

Volltextzugriff (PDF)

Abstract 12896: Safety of Transition From Tafamidis Meglumine 20 Mg to Tafamidis Free Acid 61 Mg in Patients With Transthyretin Amyloid Cardiomyopathy

Circulation (New York, N.Y.), 2020-11, Vol.142 (Suppl_3 Suppl 3), p.A12896-A12896

2020

Volltextzugriff (PDF)

Tafamidis Reduces The Decline In Longitudinal Strain And Stroke Volume In Patients With Transthyretin Amyloid Cardiomyopathy

Journal of cardiac failure, 2022-04, Vol.28 (5), p.S102-S103

2022

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(48)

Sprache

Englisch
(48)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Humans
(18)
Cardiac & Cardiovascular Systems
(16)
Cardiovascular System & Cardiology
(16)
Amyloidosis
(12)
Amyloid Neuropathies, Familial - Drug Therapy
(11)
Heart Failure
(11)
Female
(10)
Male
(10)
Tafamidis
(10)
Transthyretin
(10)
Cardiomyopathies - Drug Therapy
(9)
Cardiomyopathy
(9)
Benzoxazoles - Therapeutic Use
(8)
Double-Blind Method
(8)
Aged
(7)
Middle Aged
(7)
Heart Failure - Drug Therapy
(6)
Patients
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy

Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy

Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy

Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)

Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder

Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT

Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: Clinical and methodological implications

Reply to ‘Effects of tafamidis on heart failure hospitalization: The tale of the dog that did not bark’

Free Light-Chain Levels in Patients with Transthyretin Amyloid Cardiomyopathy in Attr-ACT

Abstract 13149: Survival Benefit With Higher Dose Tafamidis in Patients With Hereditary and Wild-type Transthyretin Amyloid Cardiomyopathy

Five-year Survival With Tafamidis In Patients With Transthyretin Amyloid Cardiomyopathy

Response by Elliott et al to Letter Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”

TAFAMIDIS DELAYS PROGRESSION OF CARDIAC DYSFUNCTION IN PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS: NON-INVASIVE PRESSURE VOLUME ANALYSIS OF THE ATTR-ACT TRIAL

EFFECT OF TAFAMIDIS ON RENAL FUNCTION IN PATIENTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN ATTR-ACT

EFFICACY OF TAFAMIDIS IN PATIENTS 80 YEARS AND OLDER WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN ATTR-ACT

Improved long‐term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms

Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy

Abstract 12239: Improvement in Measures of Disease Progression With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy

EVALUATION OF TRANSTHYRETIN TETRAMER STABILIZATION AND TTR PLASMA CONCENTRATIONS IN THE TAFAMIDIS IN TRANSTHYRETIN CARDIOMYOPATHY CLINICAL TRIAL (ATTR-ACT)

Abstract 15528: Tafamidis Free Acid 61 Mg in Patients With Transthyretin Amyloid Cardiomyopathy

Abstract 12896: Safety of Transition From Tafamidis Meglumine 20 Mg to Tafamidis Free Acid 61 Mg in Patients With Transthyretin Amyloid Cardiomyopathy

Tafamidis Reduces The Decline In Longitudinal Strain And Stroke Volume In Patients With Transthyretin Amyloid Cardiomyopathy

Suchergebnisse filtern